Skip NavigationSkip to Content
Return Return to Search Results

Synthesis of a Non-Nucleoside Reverse Transcriptase Inhibitor in the Alkenyldiarylmethane (Adam) Series With Optimized Potency and Therapeutic Index

  1. Author:
    Cushman, M.
    Casimirogarcia, A.
    Williamson, K.
    Rice, W. G.
    1. Year: 1998
  2. Journal: Bioorganic & Medicinal Chemistry Letters
    1. 8
    2. 2
    3. Pages: 195-198
  4. Type of Article: Article
  1. Abstract:

    A novel alkenyldiarylmethane (ADAM) analog has been synthesized with enhanced potency as an anti-HIV agent. The new compound (ADAM II) inhibits the cytopathic effect of HIV-1(RF) in CEM-SS cells with an EC50 of 13 nM, while it shows cytotoxicity with a CC50 of 31.6 mu M, providing a therapeutic index of 2430. ADAM II is a non-nucleoside reverse transcriptase inhibitor, displaying an IC50 of 0.3 mu M with poly(rC) oligo(dG) as the template/primer. (C) 1998 Elsevier Science Ltd. All rights reserved. [References: 17]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel